Regorafenib is an oral multikinase receptor inhibitor that blocks tyrosine kinases active in angiogenesis (VEGFR1–3 and TIE2) and cancer growth (KIT, RET, RAF1, BRAF and BFRAFV600E), growth factors (FGFR and PDGFR), and tumor immunity promoters as the colony-stimulating factor 1 receptor (CSF1R) [370]. The gene discussed is RAF1; the disease is neoplasm.